Shukra Pharmaceuticals' Q1 FY 2026-27 Quarterly Results

Result Summary

• Shukra Pharmaceuticals Ltd reported a 230.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 270.2%.
• Its expenses for the quarter were down by 14.5% QoQ and up 14.8% YoY.
• The net profit decreased 853.5% QoQ and increased 1158.3% YoY.
• The earnings per share (EPS) of Shukra Pharmaceuticals Ltd stood at 0.3 during Q1 FY 2026-27.

Financial Statments for Q1 FY 2026-27

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Shukra Pharmaceuticals Ltd is a company engaged in the pharmaceutical industry, focusing on the development, manufacturing, and marketing of pharmaceutical products. The company is known for producing a wide range of generic and branded medications aimed at treating various health conditions. Recent major developments or specific product launches in the company are not available based on the provided information. Shukra Pharmaceuticals operates in a highly competitive sector where innovation, regulatory compliance, and market demand are critical factors influencing its performance.

Revenue

In Q1FY27, Shukra Pharmaceuticals Ltd reported a total income of ₹24.06 crores. This marks a significant increase from Q4FY26, where the total income was ₹7.27 crores, reflecting a quarter-over-quarter (QoQ) growth of 230.9%. Compared to Q1FY26, where the total income was ₹6.50 crores, there is a year-over-year (YoY) growth of 270.2%. These figures indicate a substantial increase in the company's revenue over both the previous quarter and the same quarter last year. However, no specific information is provided regarding the sources or drivers of this income growth.

Profitability

Shukra Pharmaceuticals Ltd achieved a profit before tax of ₹18.17 crores in Q1FY27, which is a remarkable rise from ₹0.38 crores in Q4FY26. This represents a QoQ increase of 4681.6%. When compared to the ₹1.38 crores profit before tax in Q1FY26, the YoY increase is 1216.7%. The tax expense for Q1FY27 was ₹5.21 crores, up from ₹2.10 crores in Q4FY26 and ₹0.34 crores in Q1FY26, with respective QoQ and YoY increases of 148.1% and 1432.4%. Profit after tax was reported at ₹12.96 crores, a significant improvement from a loss of ₹1.72 crores in Q4FY26 and a profit of ₹1.03 crores in Q1FY26. The earnings per share (EPS) for Q1FY27 was ₹0.30, compared to -₹0.04 in Q4FY26 and ₹0.00 in Q1FY26, indicating a notable increase in shareholder value.

Operating Metrics

Total expenses for Shukra Pharmaceuticals Ltd in Q1FY27 were ₹5.89 crores, a decrease of 14.5% from ₹6.89 crores in Q4FY26. When compared to Q1FY26, where total expenses were ₹5.13 crores, there is an increase of 14.8%. This reflects a careful management of operating costs despite the increase in revenue. The company's ability to reduce QoQ expenses while significantly increasing revenue and profitability is highlighted in the financial data. However, specific details about the composition of these expenses or the operational strategies behind such changes are not provided in the data.